...identified for which the standard of care doomed patients to a years-long, generally fruitless diagnostic odyssey...

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...

...of their PCSK9 inhibitor Praluent alirocumab carried out prior to publication of results from the ODYSSEY...
...the launch as “responsible” and immediately included Dupixent on the National Preferred Formulary. Similarly, when ODYSSEY...
...to say about value.” Leonard Schleifer, Regeneron Pearson told BioCentury the prespecified subgroup analysis in ODYSSEY...

...NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data earlier this month from the Phase III ODYSSEY...

...Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY...
...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...

...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...
...mg/dL despite intensive statin therapy. The companies worked with ICER to provide it with the ODYSSEY...

...Reduce CV events in patients with dyslipidemia who have had acute coronary syndrome Ph III ODYSSEY...

...should be a solvable problem, because it's a systems problem," Austin said. "The current diagnostic odyssey...

...Assume that the full analysis of Amgen’s FOURIER or Regeneron Pharmaceuticals Inc. / Sanofi ’s ODYSSEY...